ClinicalTrials.gg
Active, not recruitingNCT03273413Updated May 8, 2025

Statin Therapy in Patients With Early Stage ADPKD

A Phase 4 interventional study of Pravastatin and Placebo in ADPKD and Autosomal Dominant Polycystic Kidney, sponsored by University of Colorado, Denver. Active, not recruiting at 1 site in United States. Open to participants aged 25 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-05-08.

Sponsored by University of Colorado, Denver · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
25 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver — 1 open to participants now, 5 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · University of Colorado, Denver.

Enrollment
Largest of 11
150 · median 61
Started
2017
the only one that year
Phase 4
2 of 12
none open now
Registered
5th of 12
by date

Among the 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2017, is one of 2 in phase 4, and was the 5th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

1 of the 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 25 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Polycystic Kidney, Autosomal Dominant by University of Colorado, Denver, or all of them as a file.
02

Study summary

This study plans to learn if pravastatin is helpful in slowing down the progression of kidney disease in adults with autosomal dominant polycystic kidney disease (ADPKD). Pravastatin has been approved by the Food and Drug Administration (FDA) for adults for treatment of hyperlipidemia (high cholesterol levels). The investigators are using pravastatin in this study as an investigational drug for treatment of ADPKD.

Read the detailed description

This is a randomized, double-blind, placebo-controlled trial designed to assess the efficacy and benefits of pravastatin therapy in adults with ADPKD by evaluating 1) kidney volume as measured by kidney magnetic resonance imaging (MRI); 2) renal blood flow as measured by kidney magnetic resonance angiography (MRA); 3) kidney function as assessed by Glofil-125; 4) plasma and urine protein markers that will allow a better understanding of how pravastatin works in ADPKD; and 5) blood vessel stiffness as measured by carotid-femoral pulse wave velocity. These parameters will be measured at baseline and after 2 years of pravastatin or placebo treatment in 150 patients with ADPKD.

03

Conditions studied

  • ADPKD
  • Autosomal Dominant Polycystic Kidney

Keywords

  • Pravastatin
  • Statin
04

Who can participate

Ages eligible
25 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ADPKD
  • Total kidney volume >500 mL
  • Estimated (GFR) ≥60 mL/min/1.73m\^2
  • Controlled blood pressure \<140/80 mmHg

Exclusion criteria

Exclusion Criteria:

  • Uncontrolled hypertension
  • Diabetes mellitus
  • Renal disease, renal cancer, single kidney, recent renal surgery, or acute kidney injury
  • Unstable angina
  • Coronary artery disease
  • Prior ischemic stroke
  • Other clinical indication for a statin
  • History of hospitalizations within the last 3 months
  • Hepatic impairment or liver function abnormalities
  • Secondary hypercholesterolemia or hypocholesterolemia
  • Use of tolvaptan, gemfibrozil, other fibrates, niacin, clarithromycin, or cyclosporine
  • to statins
  • therapy within the last year
  • Clinical for an MRI (i.e. implants, pacemaker, claustrophobia)
  • Hypersensitivity to iodine
  • Pregnant or breast feeding
  • Current tobacco use
  • Alcohol abuse or dependence
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants will receive inactive 40 mg tablets of placebo everyday for 6 weeks. If well tolerated, participants will continue taking inactive 40 mg dose of placebo everyday for 2 years.

    Drug: Placebo

  • Active comparator
    Pravastatin

    Participants will receive 40 mg tablets of pravastatin everyday for 6 weeks. If well tolerated, participants will continue taking 40 mg dose of pravastatin everyday for 2 years.

    Drug: Pravastatin

Interventions

  • Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy

  • DrugPlacebo

    Inactive tablet

06

What researchers measure

Primary outcomes

  1. Change in Total Kidney Volume

    Total kidney volume as assessed by renal MRI, at baseline and after 2 years of treatment

    Time frame: Baseline, 2 years

Secondary outcomes

  1. Change in Renal Blood Flow

    Renal blood flow, as assessed by renal MRA, at baseline and after 2 years of treatment

    Time frame: Baseline, 2 years

  2. Change in Kidney Function

    Glomerular filtration rate (GFR), as assessed by Glofil-125, at baseline and after 2 years of treatment

    Time frame: Baseline, 2 years

  3. Change in Circulating Inflammatory Markers

    Plasma levels of inflammatory cytokines and growth factors at baseline and after 2 years of treatment

    Time frame: Baseline, 2 years

  4. Change in Circulating Markers of Oxidative Stress

    Plasma levels of oxidative stress markers at baseline and after 2 years of treatment

    Time frame: Baseline, 2 years

  5. Change in Urinary Epithelial Cells

    Urinary epithelial cell protein expression, as assessed by immunofluorescence, at baseline and after 2 years of treatment

    Time frame: Baseline, 2 years

Other outcomes

  1. Change in Blood Vessel Stiffness

    Blood vessel stiffness, as assessed by carotid-femoral pulse wave velocity, at baseline and after 2 years

    Time frame: Baseline, 2 years

07

Study locations

1 site
08

References and documents

Publications

  • Cadnapaphornchai MA, George DM, McFann K, Wang W, Gitomer B, Strain JD, Schrier RW. Effect of pravastatin on total kidney volume, left ventricular mass index, and microalbuminuria in pediatric autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2014 May;9(5):889-96. doi: 10.2215/CJN.08350813. Epub 2014 Apr 10. PubMed 24721893 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2017 to primary completion in Mar 2024, 78 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2017
First posted
Sep 6, 2017
StartActual
Aug 31, 2017
Primary completionActual
Mar 25, 2024
CompletionEst.
Sep 30, 2025
Last update
May 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03273413
Responsible party
Sponsor
First posted
Sep 6, 2017
Start date
Aug 31, 2017
Primary completion
Mar 25, 2024
Completion
Sep 30, 2025 (estimated)
Last update
May 8, 2025

Study contacts

Michel Chonchol, MD
principal investigator · University of Colorado, Denver

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pravastatin

Start the discussion